join retatrutide trial Helped Adults With Obesity Lose Up to 30 Percent of Their Body Weight in New New GLP-3 drug significantly slashes

Researchers identified 147 adults with a body mass index 31 kg m-2 (28 kg m-2 with obesity-related comorbidity) who completed an initial 4-week BT run-in period

How PlexusDx Supports a More Personalized Approach PlexusDx recognizes that yeast infection risk during GLP-1 therapy is not uniform: genetics, immune function, and metabolic baseline significantly influence individual susceptibility

doi: 10.1056/NEJMoa2306963 18

Understanding Steady-State Concentrations Half-life directly determines how long it takes to reach steady-state medication levels, which matters for when youll experience full effects

Regulated cell death and inflammation: an auto-amplification loop causes organ failure